A Phase 3 interventional study of SOK583A1 (40 mg/mL) and Eylea EU (40 mg/mL) in Neovascular Age-related Macular Degeneration, sponsored by Sandoz. Completed at 102 sites in 16 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2024-03-26.
Sponsored by Sandoz (formerly part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing aflibercept in Macular Degeneration — 2 open to participants now, 5 under way, 2 of them phase 3. aflibercept · Macular Degeneration.
Among the 66 studies testing aflibercept in Macular Degeneration, this one is the 7th largest by enrollment, is one of 2 that started in 2021, is one of 18 in phase 3, and was the 48th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →2 of the 66 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:
Amgen · Sites in United States, Czechia, Hungary and 6 more countries
Ages 50+
Tianjin Medical University Eye Hospital
Ages 50–85
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 19 · Phase 4 27
First in 2005; this study’s year is marked. 2 started in 2021.
This study's enrollment of 485 is above the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 55 across the 66 interventional studies. Of the 48 that completed or were terminated, 28 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 66 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sandoz, one of the names counted as Novartis. Under that name alone:
Sandoz is the lead sponsor of 139 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
81 studies in Macular Degeneration by Novartis: 1 open now, 1 under way, none of them phase 3. Of 79 finished, 41 (52%) have results posted.
Among the 81 studies in Macular Degeneration by Novartis, this one is the 8th largest by enrollment of the 56 interventional ones that give a count, is one of 10 that started in 2021, is one of 23 in phase 3, and was the 61st registered.
Novartis’s Macular Degeneration studies by the year they started, since 2003.
2 of the studies testing aflibercept in Macular Degeneration that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07614776Phase 3AmgenA Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration | 2027-07-31 |
| NCT04932980Berner AugenklinikComparison of Rapid Aflibercept and Brolucizumab T&E in wAMD | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 66 studies testing aflibercept in Macular Degeneration, from their registry updates:
Among Novartis’s 81 in Macular Degeneration:
This tab as a report to print or save as PDF → With an account.
Purpose and rationale: To demonstrate similar efficacy, safety and immunogenicity of SOK583A1 and Eylea EU as per Eylea approved treatment regimen in patients with nAMD.
The primary clinical question of interest is: Does SOK583A1 have similar efficacy as Eylea EU in terms of mean change in BCVA score in participants with nAMD who are anti-VEGF naive, without important protocol deviations and adherent to the treatment and completed the treatment to Week 8?
BCVA: Best-Corrected Visual Acuity Eylea EU: Europe-authorized Eylea® nAMD: Neovascular Age-related Macular Degeneration VEGF: Vascular Endothelium Growth Factor
Participants eligible for inclusion in this study must meet all of the following criteria:
Participants meeting any of the following criteria are not eligible for inclusion in this study.
Ocular conditions and treatments:
History or evidence of the following, in the study eye:
Participants requiring anti-VEGF treatment of the fellow eye at Baseline will not be eligible for the PK substudy
Systemic conditions and treatments:
Pregnant or nursing (lactating) women and women of , defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of while taking study treatment and for 3 months after stopping the medication. Highly effective contraception methods include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intravitreal (IVT) administration of 2 mg of SOK583A1 in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.
Biological: SOK583A1 (40 mg/mL)
IVT administration of 2 mg of Eylea EU in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48. EU: European
Biological: Eylea EU (40 mg/mL)
Drug page: Aflibercept
IVT administration of 2 mg of SOK583A1 in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.
IVT administration of 2 mg of Eylea EU in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.
Best-Corrected Visual Acuity (BCVA) Will be Assessed Using the ETDRS Testing Charts at an Initial Distance of 4 Meters. The Change From Baseline in BCVA in Letters is Defined as Difference Between BCVA Score Between Week 8 and Baseline.
The primary aim of the study is to demonstrate equivalence of change in BCVA score from Baseline at Week 8 between participants with nAMD treated with SOK583A1 and participants treated with Eylea EU. The primary analysis will be performed on the Per-Protocol Set (PPS), which is the most appropriate analysis set to use when testing for equivalence. ETDRS: Early Treatment Diabetic Retinopathy Study EU: European
Time frame: Change from baseline in mean BCVA score at Week 8
Similarity in the Anatomical Outcome Between SOK583A1 and Eylea EU
Mean change in CSFT using SD-OCT from Baseline to Week 1, 4, 8, 24 and 52 CSFT: Central Subfield Thickness SD-OCT: Spectral-Domain Optical Coherence Tomography
Time frame: Week 1, 4, 8, 24 and 52
Similarity in the Anatomical Outcome Between SOK583A1 and Eylea EU
Mean change of CNV lesion size using FA from Screening to Week 8 and 52 CNV: Choroidal neovascularization FA: Fundus Angiography
Time frame: Week 8 and 52
Similarity of Efficacy Between SOK583A1 and Eylea EU in Terms of BCVA
Mean change from Baseline in BCVA score using EDTRS testing charts at Week 24 and 52
Time frame: Week 24 and 52
Similarity Between SOK583A1 and Eylea EU in Terms of Safety
Number and proportion of subjects with ocular and non-ocular Adverse Events (AEs) over 52 weeks including serious AEs, regardless of relationship to study treatment
Time frame: 52 weeks
Similarity Between SOK583A1 and Eylea EU in Terms of Immunogenicity
Development of binding and neutralizing Anti-drug antibodies (ADAs) up to Week 52
Time frame: Week 52
Systemic Exposure to SOK583A1 and Eylea EU in Participants of the Pharmacokinetic (PK) Assessment
Aflibercept concentration assessments at Baseline (pre-dose) and 24 hours after the first and third injections
Time frame: Baseline (pre-dose) and 24 hours after the first injection (day 2) and third injection (day 58)
Analysis Systemic VEGF Concentrations in Patients Treated With Aflibercept
Mean VEGF concentrations
Time frame: Assessment at Week 48 (pre-dose) and Week 52
| Milestone | SOK583A1 (40 mg/mL) | Eylea EU (40 mg/mL) |
|---|---|---|
| Started | 245 | 240 |
| Safety set | 244 | 240 |
| Full analysis set | 243 | 240 |
| Per-protocol set | 235 | 226 |
| Pk analysis set | 23 | 20 |
| Immunogenicity analysis set | 234 | 231 |
| Vegf analysis set | 60 | 67 |
| Completed | 216 | 215 |
| Not completed | 29 | 25 |
The primary aim of the study is to demonstrate equivalence of change in BCVA score from Baseline at Week 8 between participants with nAMD treated with SOK583A1 and participants treated with Eylea EU. The primary analysis will be performed on the Per-Protocol Set (PPS), which is the most appropriate analysis set to use when testing for equivalence. ETDRS: Early Treatment Diabetic Retinopathy Study EU: European
| BCVA score in letters | SOK583A1 (40 mg/mL) | Eylea EU (40 mg/mL) |
|---|---|---|
| Best-Corrected Visual Acuity (BCVA) Will be Assessed Using the ETDRS Testing Charts at an Initial Distance of 4 Meters. The Change From Baseline in BCVA in Letters is Defined as Difference Between BCVA Score Between Week 8 and Baseline. | 6.5 ± 8.98 | 6.8 ± 7.46 |
Mean change in CSFT using SD-OCT from Baseline to Week 1, 4, 8, 24 and 52 CSFT: Central Subfield Thickness SD-OCT: Spectral-Domain Optical Coherence Tomography
| μm | SOK583A1 (40 mg/mL) | Eylea EU (40 mg/mL) |
|---|---|---|
| Week 1 | -103.6 ± 89.91 | -99.2 ± 86.18 |
| Week 4 | -152.9 ± 123.55 | -140.7 ± 120.25 |
| Week 8 | -165.7 ± 144.35 | -154.2 ± 133.43 |
| Week 24 | -136.4 ± 140.19 | -127.5 ± 137.87 |
| Week 52 | -187.9 ± 150.70 | -172.9 ± 142.74 |
Mean change of CNV lesion size using FA from Screening to Week 8 and 52 CNV: Choroidal neovascularization FA: Fundus Angiography
| mm^2 | SOK583A1 (40 mg/mL) | Eylea EU (40 mg/mL) |
|---|---|---|
| Week 8 | -1.7877 ± 3.97567 | -1.7274 ± 3.77398 |
| Week 52 | -3.7845 ± 5.21911 | -3.5026 ± 4.96036 |
Mean change from Baseline in BCVA score using EDTRS testing charts at Week 24 and 52
| score on a scale | SOK583A1 (40 mg/mL) | Eylea EU (40 mg/mL) |
|---|---|---|
| Week 24 | 6.9 ± 8.93 | 7.4 ± 9.95 |
| Week 52 | 6.4 ± 11.91 | 7.7 ± 11.62 |
Number and proportion of subjects with ocular and non-ocular Adverse Events (AEs) over 52 weeks including serious AEs, regardless of relationship to study treatment
| Participants | SOK583A1 (40 mg/mL) | Eylea EU (40 mg/mL) |
|---|---|---|
| Ocular AEs in the study eye | 84 | 78 |
| Ocular AEs in the fellow eye | 55 | 51 |
| Non-ocular AEs | 141 | 141 |
Development of binding and neutralizing Anti-drug antibodies (ADAs) up to Week 52
| Participants | SOK583A1 (40 mg/mL) | Eylea EU (40 mg/mL) |
|---|---|---|
| ADA positive | 2 | 6 |
| ADA negative | 232 | 225 |
Aflibercept concentration assessments at Baseline (pre-dose) and 24 hours after the first and third injections
| ng/ml | SOK583A1 (40 mg/mL) | Eylea EU (40 mg/mL) |
|---|---|---|
| Day 1 (Baseline) | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Day 2 | 32.0 ± 24.0 | 33.3 ± 24.6 |
| Day 58 | 31.7 ± 21.9 | 33.6 ± 25.8 |
Mean VEGF concentrations
| pg/mL | SOK583A1 (40 mg/mL) | Eylea EU (40 mg/mL) |
|---|---|---|
| Week 48 (pre-dose) | 86.44 ± 77.962 | 80.09 ± 92.155 |
| Week 52 | 75.14 ± 20.892 | 73.38 ± 20.169 |
Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SOK583 | 5/244 (2%) | 39/244 (16%) | 58/244 (23.8%) |
| Eylea EU | 1/240 (0.4%) | 30/240 (12.5%) | 63/240 (26.3%) |
| Event | SOK583 | Eylea EU |
|---|---|---|
| Atrial fibrillationCardiac disorders | 4/244 | 2/240 |
| DeathGeneral disorders | 3/244 | 0/240 |
| BronchitisInfections and infestations | 0/244 | 2/240 |
| PneumoniaInfections and infestations | 0/244 | 2/240 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/244 | 2/240 |
| Coronary artery stenosisCardiac disorders | 2/244 | 0/240 |
| Retinal haemorrhageEye disorders | 2/244 | 1/240 |
| Femur fractureInjury, poisoning and procedural complications | 2/244 | 0/240 |
| Cerebral infarctionNervous system disorders | 2/244 | 0/240 |
| AnaemiaBlood and lymphatic system disorders | 1/244 | 1/240 |
| Event | SOK583 | Eylea EU |
|---|---|---|
| Neovascular age-related macular degenerationEye disorders | 25/244 | 25/240 |
| COVID-19Infections and infestations | 19/244 | 23/240 |
| HypertensionVascular disorders | 11/244 | 16/240 |
| Visual acuity reducedEye disorders | 11/244 | 12/240 |
| Age, Continuous(years) | SOK583A1 (40 mg/mL) | Eylea EU (40 mg/mL) | Total |
|---|---|---|---|
| Mean | 75.8 ± 7.82 | 75.7 ± 7.72 | 75.7 ± 7.76 |
| Age, Customized(Participants) | SOK583A1 (40 mg/mL) | Eylea EU (40 mg/mL) | Total |
|---|---|---|---|
| <75 years | 103 | 98 | 201 |
| ≥75 years | 140 | 142 | 282 |
| Sex: Female, Male(Participants) | SOK583A1 (40 mg/mL) | Eylea EU (40 mg/mL) | Total |
|---|---|---|---|
| Female | 137 | 136 | 273 |
| Male | 106 | 104 | 210 |
| Ethnicity (NIH/OMB)(Participants) | SOK583A1 (40 mg/mL) | Eylea EU (40 mg/mL) | Total |
|---|---|---|---|
| Hispanic or Latino | 12 | 9 | 21 |
| Not Hispanic or Latino | 225 | 225 | 450 |
| Unknown or Not Reported | 6 | 6 | 12 |
| Race (NIH/OMB)(Participants) | SOK583A1 (40 mg/mL) | Eylea EU (40 mg/mL) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 16 | 12 | 28 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 215 | 214 | 429 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 12 | 13 | 25 |
| Region of Enrollment(Participants) | SOK583A1 (40 mg/mL) | Eylea EU (40 mg/mL) | Total |
|---|---|---|---|
| United States | 46 | 42 | 88 |
| Europe | 158 | 161 | 319 |
| Australia | 10 | 13 | 23 |
| Israel | 15 | 12 | 27 |
| Japan | 14 | 12 | 26 |
Showing the first 100 of 102 sites across 16 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2021 to primary completion in Jul 2022, 13 months.
Results were first posted in Mar 2024, 1 year 8 months after primary completion. A results delay was requested in Jun 2023.
Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 13 months is below that.
Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept